Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.
Nadofaragene Firadenovec Sets the Stage for Gene Therapies in NMIBC
Revisit the OncLive On Air Episodes From February 2024
OncLive’s April Roundup of Key FDA Decisions in Oncology
FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC
EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer
Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist